Molecular and clinical characterization of an in frame deletion of uncertain clinical significance in the BRCA2 gene

Breast Cancer Research and Treatment

Volumn 133, Issue 2, 2012, Pages 725-734

  Rath, Michelle G ^a   Fathali Zadeh, Farnoosh ^a   Langheinz, Anne ^a,b   Tchatchou, Sandrine ^a,b   Voigtländer, Theda ^a   Heil, Jörg ^a   Golatta, Michael ^a   Schott, Sarah ^a   Drasseck, Teresa ^a   Behnecke, Anne ^a   Burgemeister, Anna Lena ^a   Evers, Christina ^a   Bugert, Peter ^a   Junkermann, Hans ^a   Schneeweiss, Andreas ^a   Bartram, Claus R ^a   Sohn, Christof ^a   Sutter, Christian ^a   Burwinkel, Barbara ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

BRCA2 gene; Hereditary breast cancer; Hereditary ovarian cancer; In frame deletion; Unclassified variant; Variant of uncertain significance

Indexed keywords

COMPLEMENTARY DNA; MESSENGER RNA; NUCLEOTIDE; PROLINE; THREONINE;

ADULT; AGED; ARTICLE; BREAST CANCER; CASE CONTROL STUDY; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTER MODEL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DNA DETERMINATION; DNA SEQUENCE; FAMILIAL CANCER; FEMALE; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENETIC VARIABILITY; HUMAN; MALE; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; ONCOGENE; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; VARIANT OF UNCERTAIN SIGNIFICANCE;

AMINO ACID SEQUENCE; BASE SEQUENCE; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COMPUTATIONAL BIOLOGY; EXONS; FAMILY; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION RATE; OVARIAN NEOPLASMS; PEDIGREE; SEQUENCE DELETION;

EID: 84863725135     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1917-0     Document Type: Article

References (50)

1. Abkevich V, Zharkikh A, Deffenbaugh AM, Frank D, Chen Y, Shattuck D, Skolnick MH, Gutin A, Tavtigian SV (2004) Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation. J Med Genet 41:492-507
2. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kalli-oniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117-1130. doi:10.1086/375033
3. Arnold N, Peper H, Bandick K, Kreikemeier M, Karow D, Teegen B, Jonat W (2002) Establishing a control population to screen for the occurrence of nineteen unclassified variants in the BRCA1 gene by denaturing high-performance liquid chromatography. J Chromatogr B 782:99-104
4. Billack B, Monteiro AN (2004) Methods to classify BRCA1 variants of uncertain clinical significance: the more the merrier. Cancer Biol Ther 3:458-459
5. Biswas K, Das R, Alter BP, Kuznetsov SG, Stauffer S, North SL, Burkett S, Brody LC, Meyer S, Byrd RA, Sharan SK (2011) A comprehensive functional characterization of BRCA2 variants associated with Fanconi anemia using mouse ES cell-based assay. Blood 118:2430-2442. doi:10.1182/blood-2010-12-324541
6. Borg A, Haile RW, Malone KE, Capanu M, Diep A, Torngren T, Teraoka S, Begg CB, Thomas DC, Concannon P, Mellemkjaer L, Bernstein L, Tellhed L, Xue S, Olson ER, Liang X, Dolle J, Borresen-Dale AL, Bernstein JL (2010) Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study. Hum Mutat 31:E1200-E1240. doi: 10.1002/humu.21202
7. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913-917. doi:10.1038/nature 03443
8. Campos B, Diez O, Domenech M, Baena M, Balmana J, Sanz J, Ramirez A, Alonso C, Baiget M (2003) RNA analysis of eight BRCA1 and BRCA2 unclassified variants identified in breast/ovarian cancer families from Spain. Hum Mutat 22:337. doi: 10.1002/humu.9176
9. Chenevix-Trench G, Healey S, Lakhani S, Waring P, Cummings M, Brinkworth R, Deffenbaugh AM, Burbidge LA, Pruss D, Judkins T, Scholl T, Bekessy A, Marsh A, Lovelock P, Wong M, Tesoriero A, Renard H, Southey M, Hopper JL, Yannoukakos K, Brown M, Easton D, Tavtigian SV, Goldgar D, Spurdle AB (2006) Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. Cancer Res 66:2019-2027. doi:10.1158/0008-5472.CAN-05- 3546
10. Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159. doi:10.1006/abio.1987. 9999
11. Consortium BCL (1999) Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 91:1310-1316
12. Cote S, Arcand SL, Royer R, Nolet S, Mes-Masson AM, Ghadirian P, Foulkes WD, Tischkowitz M, Narod SA, Proven-cher D, Tonin PN (2011) The BRCA2 c.9004G[A (E2003K) variant is likely pathogenic and recurs in breast and/or ovarian cancer families of French Canadian descent. Breast Cancer Res Treat. doi:10.1007/s10549-011-1796-4
13. Coyne RS, McDonald HB, Edgemon K, Brody LC (2004) Functional characterization of BRCA1 sequence variants using a yeast small colony phenotype assay. Cancer Biol Ther 3:453-457
14. Deffenbaugh AM, Frank TS, Hoffman M, Cannon-Albright L, Neuhausen SL (2002) Characterization of common BRCA1 and BRCA2 variants. Genet Test 6:119-121. doi:10.1089/10906 570260199375
15. Domchek S, Weber BL (2008) Genetic variants of uncertain significance: flies in the ointment. J Clin Oncol 26:16-17. doi: 10.1200/JCO.2007.14.4154
16. Figge MA, Blankenship L (2004) Missense mutations in the BRCT domain of BRCA-1 from high-risk women frequently perturb strongly hydrophobic amino acids conserved among mammals. Cancer Epidemiol Biomarkers Prev 13:1037-1041
17. Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, Murphy J, Ghadirian P, Friedman E, Foulkes WD, Kim-Sing C, Wagner T, Tung N, Couch F, Stoppa-Lyonnet D, Ainsworth P, Daly M, Pasini B, Gershoni-Baruch R, Eng C, Olopade OI, McLennan J, Karlan B, Weitzel J, Sun P, Narod SA (2006) Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 296:185-192. doi:10.1001/jama.296.2.185
18. Fleming MA, Potter JD, Ramirez CJ, Ostrander GK, Ostrander EA (2003) Understanding missense mutations in the BRCA1 gene: an evolutionary approach. Proc Natl Acad Sci USA 100:1151-1156. doi:10.1073/pnas.0237285100
19. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62:676-689
20. Hahn SA, Greenhalf B, Ellis I, Sina-Frey M, Rieder H, Korte B, Gerdes B, Kress R, Ziegler A, Raeburn JA, Campra D, Grutz-mann R, Rehder H, Rothmund M, Schmiegel W, Neoptolemos JP, Bartsch DK (2003) BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 95:214-221
21. Howard HJ, Horaitis O, Cotton RG, Vihinen M, Dalgleish R, Robinson P, Brookes AJ, Axton M, Hoffmann R, Tuffery-Giraud S (2010) The Human Variome Project (HVP) 2009 forum ''towards establishing standards''. Hum Mutat 31:366-367. doi: 10.1002/humu.21175
22. Karchin R, Monteiro AN, Tavtigian SV, Carvalho MA, Sali A (2007) Functional impact of missense variants in BRCA1 predicted by supervised learning. PLoS Comput Biol 3:e26. doi: 10.1371/journal.pcbi.0030026
23. Kuznetsov SG, Liu P, Sharan SK (2008) Mouse embryonic stem cell-based functional assay to evaluate mutations in BRCA2. Nat Med 14:875-881. doi:10.1038/nm.1719
24. Machackova E, Foretova L, Lukesova M, Vasickova P, Navratil-ova M, Coene I, Pavlu H, Kosinova V, Kuklova J, Claes K (2008) Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer. BMC Cancer 8:140. doi:10.1186/1471-2407-8-140
25. Malacrida S, Agata S, Callegaro M, Casella C, Barana D, Scaini MC, Manoukian S, Oliani C, Radice P, Barile M, Menin C, D'Andrea E, Montagna M (2008) BRCA1 p.Val1688del is a deleterious mutation that recurs in breast and ovarian cancer families from Northeast Italy. J Clin Oncol 26:26-31. doi:10.1200/JCO. 2007.13.2118
26. Marroni F, Aretini P, D'Andrea E, Caligo MA, Cortesi L, Viel A, Ricevuto E, Montagna M, Cipollini G, Federico M, Santarosa M, Marchetti P, Bailey-Wilson JE, Bevilacqua G, Parmigiani G, Presciuttini S (2004) Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations. Eur J Hum Genet 12:899-906. doi:10.1038/sj.ejhg.5201256
27. Marroni F, Aretini P, D'Andrea E, Caligo MA, Cortesi L, Viel A, Ricevuto E, Montagna M, Cipollini G, Ferrari S, Santarosa M, Bisegna R, Bailey-Wilson JE, Bevilacqua G, Parmigiani G, Presciuttini S (2004) Evaluation of widely used models for predicting BRCA1 and BRCA2 mutations. J Med Genet 41:278-285
28. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71
29. Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215
30. Mirkovic N, Marti-Renom MA, Weber BL, Sali A, Monteiro AN (2004) Structure-based assessment of missense mutations in human BRCA1: implications for breast and ovarian cancer predisposition. Cancer Res 64:3790-3797. doi:10.1158/0008-5472. CAN-03-3009
31. Narod S (2002) What options for treatment of hereditary breast cancer? Lancet 359:1451-1452. doi:10.1016/S0140-6736(02) 08465-9
32. Narod SA, Boyd J (2002) Current understanding of the epidemiology and clinical implications of BRCA1 and BRCA2 mutations for ovarian cancer. Curr Opin Obstet Gynecol 14:19-26
33. Osorio A, de la Hoya M, Rodriguez-Lopez R, Martinez-Ramirez A, Cazorla A, Granizo JJ, Esteller M, Rivas C, Caldes T, Benitez J (2002) Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancer. Int J Cancer 99:305-309. doi:10.1002/ijc.10337
34. Ostrow KL, McGuire V, Whittemore AS, DiCioccio RA (2004) The effects of BRCA1 missense variants V1804D and M1628T on transcriptional activity. Cancer Genet Cytogenet 153:177-180. doi:10.1016/j.cancergencyto.2004.01.020
35. Peelen T, van Vliet M, Bosch A, Bignell G, Vasen HF, Klijn JG, Meijers-Heijboer H, Stratton M, van Ommen GJ, Cornelisse CJ, Devilee P (2000) Screening for BRCA2 mutations in 81 Dutch breast-ovarian cancer families. Br J Cancer 82:151-156. doi: 10.1054/bjoc.1999.0892
36. Radice P, De Summa S, Caleca L, Tommasi S (2011) Unclassified variants in BRCA genes: guidelines for interpretation. Ann Oncol 22(Suppl 1):i18-i23. doi:10.1093/annonc/mdq661
37. Ramirez CJ, Fleming MA, Potter JD, Ostrander GK, Ostrander EA (2004) Marsupial BRCA1: conserved regions in mammals and the potential effect of missense changes. Oncogene 23: 1780-1788. doi:10.1038/sj.onc.1207292
38. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, Jack E, Vesprini DJ, Kuperstein G, Abrahamson JL, Fan I, Wong B, Narod SA (2001) Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68:700-710. doi: 10.1086/318787
39. Schmutzler RK, Rhiem K, Breuer P, Wardelmann E, Lehnert M, Coburger S, Wappenschmidt B (2006) Outcome of a structured surveillance programme in women with a familial predisposition for breast cancer. Eur J Cancer Prev 15:483-489. doi:10.1097/01.cej.0000220624.70234.14
40. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336: 1401-1408. doi:10.1056/NEJM199705153362001
41. Szabo C, Masiello A, Ryan JF, Brody LC (2000) The breast cancer information core: database design, structure, and scope. Hum Mutat 16:123-131. doi:10.1002/1098-1004(200008)16: 2\123:AID-HUMU4[3.0.CO;2-Y
42. Tavtigian SV, Deffenbaugh AM, Yin L, Judkins T, Scholl T, Samollow PB, de Silva D, Zharkikh A, Thomas A (2006) Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet 43:295-305. doi:10.1136/jmg.2005.033878
43. Thompson D, Easton DF, Goldgar DE (2003) A full-likelihood method for the evaluation of causality of sequence variants from family data. Am J Hum Genet 73:652-655. doi:10.1086/378100
44. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, We-itzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376:235-244. doi:10.1016/S0140-6736(10)60892-6
45. Vallon-Christersson J, Cayanan C, Haraldsson K, Loman N, Bergthorsson JT, Brondum-Nielsen K, Gerdes AM, Moller P, Kristoffersson U, Olsson H, Borg A, Monteiro AN (2001) Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families. Hum Mol Genet 10:353-360
46. Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, Roach KC, Mandell J, Lee MK, Ciernikova S, Foretova L, Soucek P, King MC (2006) Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295:1379-1388. doi:10.1001/jama.295.12.1379
47. Williams RS, Chasman DI, Hau DD, Hui B, Lau AY, Glover JN (2003) Detection of protein folding defects caused by BRCA1-BRCT truncation and missense mutations. J Biol Chem 278: 53007-53016. doi:10.1074/jbc.M310182200
48. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378: 789-792. doi:10.1038/378789a0
49. Wu K, Hinson SR, Ohashi A, Farrugia D, Wendt P, Tavtigian SV, Deffenbaugh A, Goldgar D, Couch FJ (2005) Functional evaluation and cancer risk assessment of BRCA2 unclassified variants. Cancer Res 65:417-426
50. Yang Y, Swaminathan S, Martin BK, Sharan SK (2003) Aberrant splicing induced by missense mutations in BRCA1: clues from a humanized mouse model. Hum Mol Genet 12:2121-2131. doi: 10.1093/hmg/ddg222